Science Corporation’s vision-restoring chip wins EU approval
"The thing that the space needs is a company making $100 million a year of revenue," Science Corp. CEO Max Hodak said.
Science Corp.’s vision-restoring technology has reached an important regulatory milestone in Europe, according to a TechCrunch report published through a monitored public feed.
The company’s chip, designed to help restore sight, has won approval in the European Union, marking a key step for a biotech device that has been closely watched in the health and science sectors. The feed summary tied to the report highlights a remark from Science Corp. CEO Max Hodak, who said, “The thing that the space needs is a company making $100 million a year of revenue.”
The approval signals momentum for Science Corp. as it works on technology aimed at addressing vision loss. While the feed does not provide technical or commercial details beyond the regulatory development, the EU decision suggests the company’s product has cleared an important threshold for use in one of the world’s major markets.
Science Corp. has positioned itself at the intersection of biotech, medical devices and advanced hardware, and the latest approval could help strengthen its standing in a field where clinical and regulatory progress often matters as much as engineering achievement. EU authorization is commonly viewed as a meaningful sign that a health technology has met required standards for safety or performance, depending on the product category and approval pathway.
The report is based on a monitored public feed and is attributed to TechCrunch.
Source: TechCrunch - https://techcrunch.com/2026/07/22/science-corporations-vision-restoring-chip-wins-eu-approval/
